PLEASANTON, CA — March 10, 2026
Veeva Systems announced the acquisition of Ostro, a leading AI-driven brand engagement platform for life sciences, in a deal valued at approximately $100 million in cash and equity retention grants. The acquisition marks a significant step in advancing AI-powered digital engagement across the pharmaceutical and biotech sectors, enabling healthcare brands to deliver instant, compliant information to patients and healthcare professionals through conversational interfaces.
AI-Powered Engagement for Patients and Healthcare Professionals
The acquisition strengthens Veeva’s mission to provide industry cloud solutions for life sciences, integrating advanced conversational AI, semantic search, and compliance frameworks into healthcare communication platforms. Ostro’s technology enables patients and physicians to ask questions and receive real-time answers sourced directly from approved materials, improving access to accurate medical information while maintaining strict regulatory compliance.
Unlike generic AI chat systems, Ostro’s platform operates within strict medical, legal, and regulatory (MLR) frameworks, ensuring that responses are generated only from approved and verified content. This approach eliminates the risk of AI hallucinations or unverified responses, a critical requirement for companies operating in highly regulated environments such as pharmaceuticals and biotechnology.
According to Peter Gassner, CEO of Veeva Systems, the rapid evolution of AI technologies is reshaping how people access healthcare information. He emphasized that modern engagement strategies must prioritize ease of access and accuracy of information, allowing healthcare professionals and patients to quickly obtain reliable answers without navigating complex content systems.
Advertisement
Through AI-powered chat interfaces embedded in pharmaceutical brand websites, users can instantly access relevant treatment information, educational resources, and next steps for care. These interactions generate rich engagement data, enabling life sciences organizations to better understand patient needs, optimize communication strategies, and improve digital outreach.
Strategic Integration with Veeva Commercial Cloud
Following the acquisition, Ostro will operate as an independent business unit within Veeva, led by its founder and CEO Chase Feiger, MD. Maintaining operational independence allows Ostro to continue developing specialized solutions for life sciences while gradually integrating its capabilities into the Veeva Commercial Cloud ecosystem.
Future integrations will connect Ostro’s AI engagement technology with Veeva’s commercial and field engagement applications, creating a unified platform that bridges digital interactions with in-person healthcare professional engagement. This integration aims to enhance customer centricity across the pharmaceutical commercial landscape, enabling companies to manage both online and field communications through a single workflow.
Industry analysts note that AI-driven engagement tools are becoming increasingly important in healthcare, particularly as pharmaceutical companies seek to deliver personalized and compliant communication across multiple channels. By combining Ostro’s conversational AI platform with Veeva’s extensive life sciences software infrastructure, the company aims to establish a next-generation engagement model for pharmaceutical brands.
Transforming Digital Communication in Life Sciences
The acquisition reflects a broader trend in the healthcare sector, where digital transformation and AI-driven technologies are reshaping the way information flows between companies, physicians, and patients. Platforms like Ostro are designed to remove friction from healthcare communication, making it easier for individuals to access trustworthy information without extensive searching or navigation.
Chase Feiger highlighted that the company originally built Ostro to simplify how patients and doctors obtain trusted medical information, emphasizing the importance of compliant-by-design digital experiences. By joining forces with Veeva, Ostro expects to expand its reach across a larger network of life sciences organizations, enabling more healthcare brands to adopt AI-driven engagement strategies.
Veeva currently serves over 1,500 customers globally, including many of the world’s largest biopharmaceutical companies and emerging biotech firms. As a Public Benefit Corporation, the company focuses on balancing the interests of customers, employees, shareholders, and the broader healthcare ecosystem while advancing innovation in life sciences technology.
With the integration of Ostro’s platform, Veeva is positioning itself at the forefront of AI-enabled life sciences communication, supporting the growing demand for real-time, compliant, and data-driven engagement between healthcare stakeholders. The move highlights the increasing role of artificial intelligence in transforming digital healthcare experiences, particularly within regulated industries such as pharmaceuticals and biotechnology.
z
Source: Veeva Systems press release
